Targeted cancer therapy: A comprehensive review of strategies in drug development

Targeted cancer therapy has fundamentally reshaped the landscape of oncology, moving beyond the broad cytotoxicity of traditional chemotherapy to approaches that selectively interfere with molecules or pathways critical for cancer cell survival and proliferation. This review traces the evolution of targeted therapies, beginning with the foundational understanding of cancer biology, including the journey from DNA aberrations to oncogenic proteins and the dysregulation of signal transduction pathways. It examines historical strategies such as small molecule inhibitors and monoclonal antibodies, which validated the principle of targeted intervention while also revealing the persistent challenge of therapeutic resistance. Current strategies of targeted therapy are reviewed, with a particular focus on the burgeoning field of targeted protein degradation, encompassing technologies like SERDs, PROTACs, LYTACs, PHOTACs, and molecular glues, and their distinct mechanisms for eliminating oncoproteins. The manuscript critically addresses the ongoing challenges in the field, notably the quest to drug the "undruggable" proteins and the inherent limitations of current degrader technologies. Finally, future strategies are explored, including innovative approaches to inhibit protein production by targeting mRNA, the potential of CRISPR/Cas9 gene editing for durable anti-cancer effects, the promise of epigenetic modulators, and the ongoing efforts to target elusive oncogenic transcription factors. The impact of these evolving strategies on drug development processes and their translation into clinical practice are discussed, highlighting the dynamic interplay between basic science discovery and therapeutic innovation in the quest for more effective and personalized cancer treatments.